Abstract:Imaging of apoptosis can allow noninvasive assessment of disease states and response to therapeutic intervention for a variety of diseases. The purpose of this study was to develop and evaluate a multimodal nanoplatform for the detection of apoptosis. Methods: To modulate the pharmacokinetics of annexin A5, a 36-kDa protein that binds specifically with phosphatidylserine, annexin A5 was conjugated to polyethylene glycol-coated, core-cross-linked polymeric micelles (CCPMs) dually labeled with near-infrared fluorescence fluorophores and a radioisotope (In-111). To evaluate the specificity of the binding of annexin A5-CCPM to apoptotic cells, both fluorescence microscopy and cell-binding studies were performed in vitro. Pharmacokinetics, biodistribution, dual nuclear and optical imaging, and immunohistochemical studies were performed in 2 xenografted tumor models to evaluate the potential applications of annexin A5-CCPM. Results: In cell-based studies, annexin A5-CCPM exhibited strongly specific binding to apoptotic tumor cells. This binding could be efficiently blocked by annexin A5. In mice, annexin A5-CCPM displayed a mean elimination half-life of 12.5 h. The mean initial concentration in blood was 22.4% of the injected dose/mL, and annexin A5-CCPM was mainly distributed in the central blood compartment. In mice bearing EL4 lymphoma treated with cyclophosphamide and etoposide and in mice bearing MDA-MB-468 breast tumors treated with poly(L-glutamic acid)-paclitaxel and cetuximab (IMC-C225) anti-epidermal growth factor receptor antibody, the tumor apoptosis was clearly visualized by both SPECT and fluorescence molecular tomography. In contrast, there was little accumulation of this nanoradiotracer in the tumors of untreated mice. The biodistribution data were consistent with the imaging data, with tumor-to-muscle and tumor-to-blood ratios of 38.8 and 4.1, respectively, in treated mice, and 14.8 and 2.2, respectively, in untreated mice bearing EL4 lymphoma. Moreover, further studies demonstrated that the conventional Tc-99m-labeled hydrazinonicotinamide annexin A5 and the plain CCPM control exhibited significantly lower uptake in the tumors of the treated mice than annexin A5-CCPM. Immunohistochemistry staining study showed that radioactivity count correlated with fluorescence signal from the nanoparticles, and both signals colocalized with the region of tumor apoptosis. Conclusion: Annexin A5-CCPM allowed visualization of tumor apoptosis by both nuclear and optical techniques. The complementary information acquired with multiple imaging techniques should be advantageous in assessing and validating early response to therapy.

Annexin V Conjugated Nanobubbles: A Novel Ultrasound Contrast Agent for in Vivo Assessment of the Apoptotic Response in Cancer Therapy

Preparation of Lipid Nano-Bubbles as Contrast Agent Material for Tumor Ultrasound Diagnosis of Breast Cancer

Annexin A5-functionalized nanoparticles for in vivo dual modality imaging of apoptosis

Annexin A5-conjugated polymeric micelles for dual SPECT and optical detection of apoptosis.

Advance in apoptosis imaging with annexins in tumor research

Experimental Study on Tumor Response to Chemotherapy with 18F-Sfb-annexin B1

Application of Targeted Nano-Bubble Ultrasound Contrast Agent in the Detection of Arterial Intima Inflammation in Rats

Annexin A5–Functionalized Nanoparticle for Multimodal Imaging of Cell Death

Ultrasound Contrast-Enhanced Imaging and in Vitro Antitumor Effect of Paclitaxel-Poly(lactic-co-glycolic Acid)-Monomethoxypoly (ethylene Glycol) Nanocapsules with Ultrasound-Targeted Microbubble Destruction

Ultrasound Targeted Apoptosis Imaging in Monitoring Early Tumor Response of Trastuzumab in A Murine Tumor Xenograft Model of Her-2-Positive Breast Cancer

Dual-Functional Nanodroplet for Tumor Vasculature Ultrasound Imaging and Tumor Immunosuppressive Microenvironment Remodeling

Bioactive Nanotherapeutic Ultrasound Contrast Agent for Concurrent Breast Cancer Ultrasound Imaging and Treatment

The Optimized Fabrication of Nanobubbles as Ultrasound Contrast Agents for Tumor Imaging

The Fabrication of Novel Nanobubble Ultrasound Contrast Agent for Potential Tumor Imaging

Multifunctional nanobubbles carrying indocyanine green and paclitaxel for molecular imaging and the treatment of prostate cancer

Ultrasound cavitation enhanced chemotherapy: In vivo research and clinical application

Ultrasound Molecular Imaging of Breast Cancer in MCF-7 Orthotopic Mice Using Gold Nanoshelled Poly(lactic-Co-glycolic Acid) Nanocapsules: a Novel Dual-Targeted Ultrasound Contrast Agent.

Fabricating Multifunctional Microbubbles and Nanobubbles for Concurrent Ultrasound and Photoacoustic Imaging

Dual-Targeted Microbubbles Specific to Integrin Αvβ3 and Vascular Endothelial Growth Factor Receptor 2 for Ultrasonography Evaluation of Tumor Angiogenesis.

Early Detection and Reversal of Cell Apoptosis Induced by Focused Ultrasound-Mediated Blood–Brain Barrier Opening

Detection of tumor cell apoptosis induced by chemotherapy with 99Tcm-Annexin B1